The JAK2/STAT5 pathway plays an active role in HL, where genomic gains of JAK2 are frequently observed [4], and where the suppressor of cytokine signaling 1 (SOCS1), a negative regulator of JAK/STAT signaling, appears mutated and inactivated [5]. This evidence concerns the gene JAK2 and Hodgkins lymphoma.